- Home
- REPL vs IRMD Comparison
REPL vs IRMD Comparison
Compare REPL & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- IRMD
- Stock Information
- Founded
- REPL 2015
- IRMD 1992
- Country
- REPL United States
- IRMD United States
- Employees
- REPL N/A
- IRMD N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- IRMD Medical/Dental Instruments
- Sector
- REPL Health Care
- IRMD Health Care
- Exchange
- REPL Nasdaq
- IRMD Nasdaq
- Market Cap
- REPL 757.8M
- IRMD 668.2M
- IPO Year
- REPL 2018
- IRMD 2014
- Fundamental
- Price
- REPL $9.35
- IRMD $59.96
- Analyst Decision
- REPL Strong Buy
- IRMD Strong Buy
- Analyst Count
- REPL 7
- IRMD 1
- Target Price
- REPL $20.83
- IRMD $72.00
- AVG Volume (30 Days)
- REPL 1.1M
- IRMD 62.0K
- Earning Date
- REPL 08-07-2025
- IRMD 07-31-2025
- Dividend Yield
- REPL N/A
- IRMD 1.13%
- EPS Growth
- REPL N/A
- IRMD 10.72
- EPS
- REPL N/A
- IRMD 1.55
- Revenue
- REPL N/A
- IRMD $75,154,639.00
- Revenue This Year
- REPL N/A
- IRMD $10.62
- Revenue Next Year
- REPL N/A
- IRMD $9.69
- P/E Ratio
- REPL N/A
- IRMD $38.70
- Revenue Growth
- REPL N/A
- IRMD 11.04
- 52 Week Low
- REPL $6.44
- IRMD $42.34
- 52 Week High
- REPL $17.00
- IRMD $63.29
- Technical
- Relative Strength Index (RSI)
- REPL 49.55
- IRMD 64.98
- Support Level
- REPL $8.92
- IRMD $57.50
- Resistance Level
- REPL $9.93
- IRMD $60.94
- Average True Range (ATR)
- REPL 0.52
- IRMD 1.49
- MACD
- REPL -0.08
- IRMD -0.03
- Stochastic Oscillator
- REPL 22.40
- IRMD 94.08
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.